Adjuvant treatment of non-small-cell lung cancer: How do we improve the cure rates further?

ONCOLOGY

Volumn 21, Issue 2, 2007, Pages 163-171

  Wozniak, Antoinette J ^a,c   Gadgeel, Shirish M ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; IFOSFAMIDE; LEVAMISOLE; MITOMYCIN; MOLECULAR MARKER; NAVELBINE; PACLITAXEL; TUMOR MARKER; UFT; VINDESINE;

BLEEDING; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEATH; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PROTEOMICS; RANDOMIZATION; REVIEW; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY;

EID: 33847207764     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909, 1995.
3. Holmes EC, Gail M, for the Lung Cancer Study Group: Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 4:710-715, 1986.
4. Lad T, Rubinstein L, Sadeghi A, et al: The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer. J Clin Oncol 6:9-17, 1988.
5. Feld R, Rubinstein L, Thomas PA, and the Lung Cancer Study Group: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I NSCLC. J Natl Cancer Inst 85:299-306, 1993.
6. Niiranen A, Niitamo-Korhonen S, Kouri M, et al: Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: A randomized study. J Clin Oncol 10:1927-1932, 1992.
7. Keller SM, Adak S, Wagner H, et al: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or III non-small cell lung cancer. N Engl J Med 343:1217-1222, 2000.
8. PORT Meta-analysis Trialists' Group: Postoperative radiotherapy in non-small-cell lung cancer: Systemic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352:257-263, 1998.
9. Scagliotti GV, Fossati R, Torn V, et al: Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst 95:1453-1461, 2003.
10. Waller D, Peake MD, Stephens RJ, et al: Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26:173-182, 2004.
11. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
12. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005.
13. Douillard J, Rosell R, Delena M, et al: ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association (abstract 7013). J Clin Oncol 23(16S):624s, 2005.
14. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 (abstract 7019). Proc Am Soc Clin Oncol 23:621, 2004.
15. Strauss GM, Herndon JE, Maddaus MA, et al: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract 7007). J Clin Oncol 24(18S):365s, 2006.
16. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients (abstract 7008). J Clin Oncol 24(18S):366s, 2006.
17. Ardizzoni A, Tiseo M, Boni L, et al: CISCA (cisplatin vs carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) (abstract 7011). J Clin Oncol 24(18S):366s, 2006.
18. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004.
19. Hamada C, Tanaka F, Ohta M, et al: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23:4999-5006, 2005.
20. Roth JA, Atkinson EN, Fossella F, et al: Long term follow-up of patients enrolled in a randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 21:1-6, 1998.
21. Rosell R, Gomez-Codina J, Camps C, et al: Preresectional chemotherapy in stage IIIA non-small cell lung cancer: A 7-year assessment of a randomized controlled trial. Lung Cancer 26:7-14, 1999.
22. Depierre A, Milleron B, Moro-Sibilot D, et al: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA NSCLC. J Clin Oncol 20:247-253, 2002.
23. Pisters KM, Ginsberg RJ, Giroux DJ, et al: Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119:429-439, 2000.
24. Pisters KM, Ginsberg RJ, Giroux DJ, et al: Bimodality lung oncology team (BLOT) trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer (NSCLC): Long term followup of a phase II trial (abstract 2544). Proc Am Soc Clin Oncol 22:633, 2003.
25. Pisters K, Vallieres E, Bunn P, et al: S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results (abstract 7012). J Clin Oncol 23(16S):624s, 2005.
26. The Lung Cancer Study Group: Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 315:1377-1381, 1986.
27. Sawyer TE, Bonner JA, Gould PM, et al: Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 64:1402-1408, 1997.
28. Machtay M, Lee JH, Sjrager JB, et al: Risk of death from intercurrent disease is not excessively increased by modern post-operative radiotherapy for high risk resected non-small cell lung carcinoma. J Clin Oncol 19:3912-3917, 2001.
29. Rosell R, de Lena M, Carpagnano F, et al: ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts). Lung Cancer 49(suppl 2):S3-S4, 2005.
30. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995.
31. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29(suppl 16):10-14, 2002.
32. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005.
33. Fontanini G, Lucchi M, Vignati S, et al: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. J Natl Cancer Inst 89:881-886, 1997.
34. Yuan A, Yu CJ, Kuo SH, et al: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432-441, 2001.
35. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern cooperative oncology group trial - E4599 (abstract LBA4). J Clin Oncol 23(16S):2s, 2005.
36. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004.
37. Skillings JR, Johnson DH, Miller K, et al: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (abstract 3019). J Clin Oncol 23(16S):196s, 2005.
38. Paavonen K, Puolakkainen P, Jussila L, et al: Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156:1499-1504, 2000.
39. Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284:122-130, 2003.
40. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase Q trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 21:2237-2246, 2003.
41. Kris M, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158, 2003.
42. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3234-3247, 2004.
43. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005.
44. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004.
45. Kris MG, Sandler A, Miller V, et al: Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalevolar carcinoma (abstract 7062). J Clin Oncol 23:628, 2004.
46. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004.
47. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004.
48. Cappuzzo F, Hirsch F, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005.
49. Kelly K, Gaspar L, Chansky K, et al: Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer (abstract 7058). J Clin Oncol 23(16S):634s, 2005.
50. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005.
51. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early stage non-small cell lung cancer. N Engl J Med 355:50-580, 2006.
52. Kikuchi T, Massion PP, Shyr Y, et al: Proteomic analysis of lung cancer tumors (abstract 7028). J Clin Oncol 24(18s):371s, 2006.
53. Reed E: ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11:6100-6102, 2005.
54. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006.
55. Rosell R, Cecere F, Santarpia M, et al: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 6:323-331, 2006.
56. Bepler G, Zheng Z, Gautam A, et al: Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47:183-192, 2005.